{"id":"brentuximab","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01461538","NCT04213209","NCT03205891","NCT03057795","NCT02499627","NCT03719105","NCT05414500","NCT01940796","NCT01620229","NCT02744612","NCT06507514","NCT06563778","NCT03652441","NCT06857500","NCT04378647","NCT05180097","NCT03527628","NCT02616965","NCT01780662","NCT06201507","NCT01777152","NCT03540849","NCT02423291","NCT01950364","NCT03013933","NCT02408042","NCT02588651","NCT02244021","NCT01712490","NCT03587844","NCT05316246","NCT01841021","NCT06186986","NCT02581631","NCT01771107","NCT01851200","NCT02280993","NCT05006664","NCT05886478","NCT01900496","NCT03373305","NCT03302728","NCT02098512","NCT07467317","NCT07258680","NCT01716806","NCT02533570","NCT01700751","NCT02280785","NCT03576378"],"aliases":["Brentuximab Vedotin","Adcetris"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"This drug has been discontinued. Further clinical information is unavailable due to the discontinuation of the trial.","brandName":"Brentuximab","companyId":"university-of-arizona","ecosystem":[],"mechanism":{"target":"Tumor necrosis factor receptor superfamily member 8, Tubulin beta","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","oneSentence_ai":"The mechanism of action for Brentuximab is unknown.","technicalDetail":""},"commercial":null,"references":[],"ai_enriched":true,"biosimilars":[],"companyName":"University of Arizona","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Brentuximab","indications":{"approved":[{"name":"Anaplastic large T-cell systemic malignant lymphoma","diseaseId":"anaplastic-large-t-cell-systemic-malignant-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"CD30-positive peripheral T-cell lymphoma","diseaseId":"cd30-positive-peripheral-t-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Cutaneous Tcell lymphoma","diseaseId":"cutaneous-tcell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hodgkin's disease","diseaseId":"hodgkin's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01461538","phase":"Phase 2","title":"A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies","status":"COMPLETED","sponsor":"Seagen Inc.","isPivotal":false,"enrollment":84,"indication":"Acute Lymphoid Leukemia, Acute Myeloid Leukemia","completionDate":"2014-12"},{"nctId":"NCT04213209","phase":"N/A","title":"Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 Milligrams \"Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Hodgkin Lymphoma (Only Pediatric Patients)\"","status":"COMPLETED","sponsor":"Takeda","isPivotal":false,"enrollment":95,"indication":"Peripheral T Cell Lymphoma, Pediatric Hodgkin Lymphoma","completionDate":"2023-12-13"},{"nctId":"NCT03205891","phase":"Phase 1","title":"An Open Label Phase I Study of Brentuximab Vedotin Plus TAK228 for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphom","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":0,"indication":"Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Classical Hodgkin Lymphoma","completionDate":"2021-03"},{"nctId":"NCT03057795","phase":"Phase 2","title":"A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":62,"indication":"Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma","completionDate":"2026-03-25"},{"nctId":"NCT02499627","phase":"Phase 2","title":"A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","isPivotal":false,"enrollment":43,"indication":"Lymphatic Diseases","completionDate":"2020-06-30"},{"nctId":"NCT03719105","phase":"EARLY/Phase 1","title":"Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lym","status":"RECRUITING","sponsor":"New York Medical College","isPivotal":false,"enrollment":40,"indication":"NK-Cell Lymphoma, NK-Cell Leukemia","completionDate":"2028-12-31"},{"nctId":"NCT05414500","phase":"Phase 1","title":"Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":10,"indication":"Cutaneous T Cell Lymphoma, Mycosis Fungoides","completionDate":"2026-07-31"},{"nctId":"NCT01940796","phase":"Phase 1","title":"Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)","status":"TERMINATED","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":19,"indication":"Graft-vs-Host Disease, GVHD","completionDate":"2016-12"},{"nctId":"NCT01620229","phase":"Phase 1","title":"Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":0,"indication":"Hematopoietic/Lymphoid Cancer","completionDate":""},{"nctId":"NCT02744612","phase":"Phase 2","title":"A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":39,"indication":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","completionDate":"2024-07-30"},{"nctId":"NCT06507514","phase":"Phase 1","title":"Safety and Efficacy of Blinatumomab and Autologous HSCT Sandwich Strategy as Consolidation Therapy for B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":4,"indication":"B-cell Acute Lymphoblastic Leukemia","completionDate":"2030-04-01"},{"nctId":"NCT06563778","phase":"Phase 2","title":"A Randomized, Open-label, Phase 2 Trial of Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","isPivotal":false,"enrollment":100,"indication":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","completionDate":"2028-09-01"},{"nctId":"NCT03652441","phase":"Phase 2","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","isPivotal":false,"enrollment":14,"indication":"Classical Hodgkin Lymphoma","completionDate":"2025-01-25"},{"nctId":"NCT06857500","phase":"N/A","title":"Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience","status":"COMPLETED","sponsor":"Federico II University","isPivotal":false,"enrollment":200,"indication":"Classic Hodgkin Lymphoma, Advanced Hodgkin Lymphoma","completionDate":"2025-01-30"},{"nctId":"NCT04378647","phase":"Phase 2","title":"A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy With Brentuximab Vedotin-ESHAP vs ESHAP in Patients With Relapsed / Refractory Classical Hodgkin's Lymphoma, Followed by Brentuxima","status":"RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","isPivotal":false,"enrollment":150,"indication":"Hodgkin Lymphoma, Adult","completionDate":"2026-08-30"},{"nctId":"NCT05180097","phase":"Phase 2","title":"A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin L","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","isPivotal":false,"enrollment":84,"indication":"Hodgkin Lymphoma","completionDate":"2026-12-31"},{"nctId":"NCT03527628","phase":"Phase 2","title":"A Phase II, Multicenter, Open Label Study of Treatment Intensification With ACVD and Brentuximab-Vedotin in Advanced-stage Hodgkin Lymphoma Patients With a Positive Interim PET Scan After 2 ABVD Cycle","status":"UNKNOWN","sponsor":"King Abdullah International Medical Research Center","isPivotal":false,"enrollment":220,"indication":"Classical Hodgkin Lymphoma, Hodgkin Lymphoma (Category)","completionDate":"2022-01-15"},{"nctId":"NCT02616965","phase":"Phase 1","title":"A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","isPivotal":false,"enrollment":16,"indication":"Cutaneous T-cell Lymphoma (CTCL)","completionDate":"2024-01-31"},{"nctId":"NCT01780662","phase":"Phase 1","title":"A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":46,"indication":"Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma","completionDate":"2021-09-30"},{"nctId":"NCT06201507","phase":"Phase 2","title":"Efficacy and Safety of Modified BV-AVD-R Regimen in Chinese Children With Previously Untreated Intermediate- and High-risk Classical Hodgkin's Lymphoma: an Open Label, Non-randomized, Single-arm, Phas","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","isPivotal":false,"enrollment":44,"indication":"Hodgkin Lymphoma","completionDate":"2025-12-31"},{"nctId":"NCT01777152","phase":"Phase 3","title":"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas","status":"COMPLETED","sponsor":"Seagen Inc.","isPivotal":true,"enrollment":452,"indication":"Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma","completionDate":"2020-10-02"},{"nctId":"NCT03540849","phase":"Phase 2","title":"Maintenance Brentuximab Vedotin (Bv) Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma Patient: A Prospective, Multicenter, Phase II Study.","status":"UNKNOWN","sponsor":"University Hospital, Caen","isPivotal":false,"enrollment":58,"indication":"Hodgkin Lymphoma","completionDate":"2023-03-07"},{"nctId":"NCT02423291","phase":"Phase 2","title":"A Phase II Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL)","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","isPivotal":false,"enrollment":15,"indication":"Primary Mediastinal Large B Cell Lymphoma","completionDate":"2016-07"},{"nctId":"NCT01950364","phase":"Phase 1","title":"A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymph","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","isPivotal":false,"enrollment":20,"indication":"Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma","completionDate":"2015-06"},{"nctId":"NCT03013933","phase":"Phase 1","title":"A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":29,"indication":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","completionDate":"2022-05-24"},{"nctId":"NCT02408042","phase":"Phase 1","title":"A Phase Ib/II Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)","status":"WITHDRAWN","sponsor":"Western Regional Medical Center","isPivotal":false,"enrollment":0,"indication":"Lymphoma, Hodgkin's Lymphoma","completionDate":"2015-11"},{"nctId":"NCT02588651","phase":"Phase 2","title":"A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)","status":"COMPLETED","sponsor":"Deepa Jagadeesh","isPivotal":false,"enrollment":23,"indication":"T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","completionDate":"2024-10-14"},{"nctId":"NCT02244021","phase":"Phase 2","title":"A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","isPivotal":false,"enrollment":13,"indication":"Relapsed/Refractory Hodgkin's Lymphoma","completionDate":"2017-10"},{"nctId":"NCT01712490","phase":"Phase 3","title":"A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Takeda","isPivotal":true,"enrollment":1334,"indication":"Hodgkin Lymphoma","completionDate":"2026-02-02"},{"nctId":"NCT03587844","phase":"Phase 2","title":"Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":58,"indication":"Mycosis Fungoides, Lymphomatoid Papulosis","completionDate":"2027-07"},{"nctId":"NCT05316246","phase":"Phase 2","title":"Efficacy and Safety of Brentuximab Vedotin in Combination With Tislelizumab for the Treatment of CD30-positive Relapsed/Refractory NK/T-cell Lymphoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","isPivotal":false,"enrollment":40,"indication":"NK/T Cell Lymphoma Nos","completionDate":"2024-12-31"},{"nctId":"NCT01841021","phase":"NA","title":"Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","isPivotal":false,"enrollment":1,"indication":"Peripheral T-Cell Lymphoma","completionDate":"2016-06"},{"nctId":"NCT06186986","phase":"Phase 3","title":"Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate Brentuximab Biodistribution in CD30-positive Lymphoma","status":"UNKNOWN","sponsor":"University Medical Center Groningen","isPivotal":true,"enrollment":20,"indication":"Diffuse Large B-cell-lymphoma","completionDate":"2026-01"},{"nctId":"NCT02581631","phase":"Phase 1","title":"A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":145,"indication":"Non-Hodgkin's Disease","completionDate":"2022-02-07"},{"nctId":"NCT01771107","phase":"Phase 1","title":"A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":41,"indication":"AIDS-Related Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma","completionDate":"2024-03-21"},{"nctId":"NCT01851200","phase":"Phase 2","title":"Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial.","status":"COMPLETED","sponsor":"Fondazione Michelangelo","isPivotal":false,"enrollment":9,"indication":"Germ Cell Cancer","completionDate":"2017-09"},{"nctId":"NCT02280993","phase":"Phase 1","title":"Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are E","status":"UNKNOWN","sponsor":"Marjolein Spiering","isPivotal":false,"enrollment":72,"indication":"Hodgkin Lymphoma, Refractory","completionDate":"2020-05"},{"nctId":"NCT05006664","phase":"Phase 2","title":"A Phase II Open Label Study of Brentuximab Vedotin in Combination With CHEP in Patients With Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)","status":"UNKNOWN","sponsor":"Czech Lymphoma Study Group","isPivotal":false,"enrollment":33,"indication":"Lymphoma, T-Cell, Peripheral","completionDate":"2024-10"},{"nctId":"NCT05886478","phase":"N/A","title":"Real-World Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma Patients","status":"COMPLETED","sponsor":"Takeda","isPivotal":false,"enrollment":26,"indication":"T-Cell Lymphoma","completionDate":"2024-10-31"},{"nctId":"NCT01900496","phase":"Phase 1","title":"Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":6,"indication":"Lymphoma","completionDate":"2017-07"},{"nctId":"NCT03373305","phase":"Phase 1","title":"A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":0,"indication":"CD30-Positive Neoplastic Cells Present, Folliculotropic Mycosis Fungoides","completionDate":"2019-04-26"},{"nctId":"NCT03302728","phase":"Phase 1","title":"A Phase 1b Study of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-cell Lymphoma, CD30-positive Peripheral T-cell Lymphoma, or CD30-positive Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","isPivotal":false,"enrollment":6,"indication":"Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral","completionDate":"2021-08-02"},{"nctId":"NCT02098512","phase":"Phase 1","title":"A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ H","status":"UNKNOWN","sponsor":"New York Medical College","isPivotal":false,"enrollment":20,"indication":"Hodgkin Lymphoma","completionDate":"2022-12-31"},{"nctId":"NCT07467317","phase":"N/A","title":"FIL_BREAL: BV-CHP Real-life and Biological Evidences in Patients With sALCL","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","isPivotal":false,"enrollment":100,"indication":"Anaplastic Large Cell Lymphoma","completionDate":"2028-05"},{"nctId":"NCT07258680","phase":"Phase 3","title":"Optimization of the First-line Therapy of T-cell Lymphomas","status":"ENROLLING_BY_INVITATION","sponsor":"N.N. Petrov National Medical Research Center of Oncology","isPivotal":true,"enrollment":114,"indication":"Peripheral T-cell Lymphoma","completionDate":"2028-12"},{"nctId":"NCT01716806","phase":"Phase 2","title":"A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Co","status":"COMPLETED","sponsor":"Seagen Inc.","isPivotal":false,"enrollment":131,"indication":"Hodgkin Disease, Peripheral T Cell Lymphoma","completionDate":"2023-09-12"},{"nctId":"NCT02533570","phase":"Phase 2","title":"A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Seagen Inc.","isPivotal":false,"enrollment":20,"indication":"Systemic Lupus Erythematosus","completionDate":"2017-06-05"},{"nctId":"NCT01700751","phase":"Phase 1","title":"A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":17,"indication":"Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute","completionDate":"2016-11-21"},{"nctId":"NCT02280785","phase":"Phase 2","title":"A Phase II Study of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":33,"indication":"Non-Hodgkin Lymphoma","completionDate":"2018-09"},{"nctId":"NCT03576378","phase":"Phase 1","title":"A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymph","status":"UNKNOWN","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","isPivotal":false,"enrollment":41,"indication":"Hodgkin Lymphoma","completionDate":"2024-10-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":36,"withResults":14},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}